Citadel Advisors
SVA

Citadel Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Citadel Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,000
Closed -$5K – 9559
2015
Q1 		$5K Hold
1,000
– – ﹤0.01% 8345
2014
Q4 		$5K Sell
1,000
-3,000
-75% -$15.3K ﹤0.01% 8295
2014
Q3 		$19K Sell
4,000
-200
-5% -$1.07K ﹤0.01% 7514
2014
Q2 		$24K Buy
4,200
+2,500
+147% +$15.2K ﹤0.01% 7220
2014
Q1 		$12K Sell
1,700
-8,600
-83% -$56.9K ﹤0.01% 7483
2013
Q4 		$63K Buy
10,300
+1,700
+20% +$10.2K ﹤0.01% 5917
2013
Q3 		$51K Sell
8,600
-5,600
-39% -$26.8K ﹤0.01% 5790
2013
Q2 		$56K Buy
+14,200
New +$52.8K ﹤0.01% 5610

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SVA Position: Q4 2017 in Review

Citadel Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 34,193 shares — an estimated $256K sold.

Citadel Advisors first reported a position in SVA in Q2 2013 and held it in 10 quarters. The position peaked at $958K in Q2 2014. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Citadel Advisors reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
  • Citadel Advisors sold 34,193 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $256K.
  • Citadel Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 10 quarters.
  • Citadel Advisors's Sinovac Biotech, Ltd position peaked at $958K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.